Follow-up results of transvenous occlusion of patent ductus arteriosus with the buttoned device11One of the authors of this article (EBS) is the inventor of the device used in this study.  by Rao, P.Syamasundar et al.
Pediatric Cardiology
Follow-Up Results of
Transvenous Occlusion of Patent
Ductus Arteriosus with the Buttoned Device
P. Syamasundar Rao, MD, FACC,*† Seong Ho Kim, MD,‡ Jae-Young Choi, MD,§ Christian Rey, MD,\
Jorge Haddad, MD,¶ Francois Marcon, MD,# Kevin Walsh, MD,** Eleftherios B. Sideris, MD††
Madison, Wisconsin; St. Louis, Missouri; Puchon, Seoul, Korea; Lille, France; Ribeira˜o Preto, Brazil; Nancy,
France; Liverpool, United Kingdom; and Athens, Greece
OBJECTIVES The purpose of this presentation is to document results of buttoned device (BD) occlusion of
patent ductus arteriosus (PDA) in a large number of patients with particular emphasis on
long-term follow-up in an attempt to provide evidence for feasibility, safety and effectiveness
of this method of PDA closure.
BACKGROUND Immediate and short-term results of BD occlusion of PDA have been documented in a
limited number of children.
METHODS During a six-year period ending August 1996, transcatheter BD closure of PDA was attempted
in 284 patients, ages 0.3 to 92 years (median 7) under a protocol approved by the local institutional
review boards and FDA with an investigational device exemption in U.S. cases.
RESULTS The PDAs measured 1 to 15 mm (median 4) at the narrowest diameter; 20 were larger than
8 mm and 10 larger than 10 mm. They were occluded with devices measuring from 15 to
35 mm delivered via 7F (N 5 140) or 8F (N 5 144) sheaths. Successful implantation of the
device was accomplished in 278 (98%) of 284 patients. The Qp:Qs decreased from 1.8 6 0.6
(mean 6 SD) to 1.09 6 0.19 (p , 0.001). Effective occlusion defined as no (N 5 167 [60%])
or trivial (N 5 79 [28%]) residual shunt was achieved in 246 (88%) patients. All types of
PDAs, irrespective of the shape (conical, tubular or short), size (small or large) or length
(short or long) of the PDA and previously implanted Rashkind devices, could be occluded.
Follow-up data, 1 to 60 months (median 24) after device implantation, were available in 234
(84%) patients. Seven (3%) patients required reintervention to treat residual shunt with (N 5
2) or without (N 5 5) hemolysis. Actuarial reintervention-free rates were 95% at 1 and 5
years. There was gradual reduction of actuarial residual shunts and were 40%, 28%, 21%, 14%,
11%, 10%, 6% and 0% respectively at 1 day, 1, 6, 12, 24, 36, 48 and 60 months after device
implantation. Incorporation of folding plug over the button loop in 10 additional patients
produced immediate and complete occlusion of PDA.
CONCLUSIONS This large multiinstitutional experience confirms the feasibility, safety and effectiveness of
buttoned device closure of PDAs. All types of PDAs irrespective of the shape, length and
diameter can be effectively occluded. Incorporation of folding plug over the button loop
produces complete PDA occlusion at the time of device implantation. (J Am Coll Cardiol
1999;33:820–6) © 1999 by the American College of Cardiology
Immediate and short-term results of transvenous occlusion of
patent ductus arteriosus (PDA) with the buttoned device (BD)
have, in a limited number of patients, demonstrated feasibility,
safety and effectiveness of this method (1–3). However, long-
term results have not been documented. The purpose of this
study is: 1) to present the data on larger number of patients
than that in our preliminary study (2), 2) to document
long-term follow-up results of PDA occlusion with the BD in
an attempt to assess long-term efficacy and safety of this
procedure, and 3) to evaluate efficacy of folding plug modifi-
cation of the BD in producing complete closure of large PDAs.
PATIENTS AND METHODS
During a six-year period from September 1990 to August
1996, 284 patients were taken to the catheterization labo-
ratory with the intent to occlude PDA with BD.
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Protocol. The procedure was performed under a protocol
approved by the Institutional Review Board at each insti-
tution, as per local regulations and FDA approval for
clinical trials with investigational device exemption in U.S.
cases.
Inclusion/exclusion criteria. Patients with clinical and
echo-Doppler features of PDA that are ordinarily candi-
dates for surgical closure are included. The so-called “silent
ductus” cases (4,5) are excluded. Otherwise, ductal size and
shape are not the bases for exclusion. Ten patients with
persistent shunt following previous Rashkind device (6,7)
implantation for PDA closure were also included. Ducti
associated with complex cyanotic heart defects and those
with pulmonary vascular obstructive disease are excluded.
Device. The buttoned device (Custom Medical Devices,
Amarillo, Texas and Athens, Greece) consists of three
components: 1) occluder, 2) counter-occluder and 3) deliv-
ery system and has been described in detail previously (2).
During the last one-half of cases, however, the device was
modified such that both the knots (buttons) attached to
occluder were made radiopaque with spring buttons. The
devices are produced in several sizes, from 15 mm through
40 mm, in 5 mm increments.
Procedure. After clinical and echocardiographic diagnosis
and informed consent, cardiac catheterization and aortog-
raphy percutaneously via femoral vein and artery were
performed to confirm the clinical diagnosis and to delineate
the ductal size and shape. Minimal ductal diameter was
measured in the lateral view, corrected for magnification,
compared with the diameter of the angiographic catheter.
Heparin (100 units/kg) was administered intravenously and
a 7-F (for 15 mm devices) or an 8F (for devices larger than
15 mm) long sheath (Cordis, Miami, Florida or Cook,
Bloomington, Indiana) was introduced transvenously and its
tip positioned in the descending aorta across the ductus.
Again, the method of device implantation has been
described in detail previously (2) and will only be outlined
here. The occluder component of the device was folded
and introduced into the sheath and advanced with a 7F
pusher catheter and delivered into the descending aorta.
The sheath and the occluder were withdrawn such that
the occluder lies against the aortic end of the ductus and
the sheath tip is in the main pulmonary artery. The
counter-occluder was threaded over the delivery wire, but
within the sheath and delivered into the main pulmonary
artery. By gently pulling the delivery wire and the
occluder simultaneously with advancing the counter-
occluder with the tip of the sheath, the occluder and
counter-occluder were buttoned across the ductus. Veri-
fication that buttoning has occurred was made by fluo-
roscopic demonstration of the passage of radiopaque wire
of the counter-occluder beyond the radiopaque button(s).
If the ductus was short, buttoning across both buttons
was performed. If the ductus was long, buttoning across
the proximal button (farthest from the occluder) was
considered adequate. The delivery wire was cut and
removed, followed by withdrawal of the nylon thread,
thus disconnecting the device from the delivery wire.
Following device implantation, oximetry and aortography
were performed to evaluate the residual shunt. Three doses
of Cefazolin (25 mg/kg/dose) were administered intrave-
nously. Aspirin (5 to 10 mg/kg/day) administered orally was
given for a six-week period.
Follow-up. Clinical evaluation, chest X-ray and
echocardiography-Doppler studies were performed 1 day, 1,
6 and 12 months after the device implantation and yearly
thereafter. These were performed by the interventional
cardiologist, radiologist and echocardiographer respectively,
at the participating medical center. Clinical evaluation
scrutinized for physical findings indicative of residual shunt
and need for reintervention. Chest roentgenograms were
reviewed for device position and to exclude wire fractures.
Echocardiography-Doppler studies were performed to de-
tect and quantitate residual shunt (Table 1) and to exclude
Abbreviations and Acronyms
BD 5 buttoned device
PDA 5 patent ductus arteriosus
Table 1. Quantitation of Residual Ductal Shunt
None — No residual shunt
Trivial — Color Doppler jet width #1 mm at the origin of the shunt
No left ventricular volume overload*
Small — Color Doppler jet width of residual shunt between 1 to 2 mm
No left ventricular volume overload*
Medium — Color Doppler jet width of residual shunt 2 to 4 mm
Left ventricular volume overload* may be present
Large — Color Doppler jet width of residual shunt .4 mm
Left ventricular volume overload* is present
*Left ventricular volume overload is defined as left atrium to aortic root ratio .1.2 and enlargement of the left atrium and left
ventricle (.95 percentile for age).
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obstruction in the left pulmonary artery and descending
aorta.
Definitions. Complete occlusion is defined as having no
residual shunt whatsoever by the modality of the evaluation
whether it be aortography or Doppler evaluation. Effective
occlusion is deemed to have been achieved if there was
complete occlusion (no residual shunt) or trivial residual
shunt (see Table 1 for definition) on echocardiography-
Doppler studies. Residual shunt by echocardiography-Dopp-
ler studies was quantitated as per the guidelines listed in
Table 1.
Folding plug buttoned device. Following preliminary
analysis of the results (8) with high incidence of residual
shunt, the device was modified such that a polyurethane
foam plug was incorporated over the button loop (Fig. 1).
Ten patients underwent PDA closure with this modified
device.
Statistical methods. The data are expressed as mean 6 SD
for normally distributed variables. Median and ranges are
given for data that are not normally distributed. Paired t
tests were used to compare pre- versus post-closure values.
Categorical data were compared using chi-square tests.
Actuarial evaluation of event-free rates and residual shunts
was performed by Kaplan-Meier method. The level of
statistical significance was set at p , 0.05.
RESULTS
Study subjects. Two hundred and eighty four patients ages
4 months to 92 years (median 7 years) were taken to the
catheterization laboratory with the intent to perform trans-
catheter BD occlusion of their PDA during a six-year period
ending August 1996 at 21 institutions around the world
(Appendix). The number of patients undergoing the pro-
cedure at these institutions varied between 3 and 79 (median
6). Their weights ranged between 5 and 90 kg with a
median of 19 kg. Fourteen children (1,2) and one adult (3)
have been included in our previous reports.
PDAs and devices. The size of the PDA, measured at its
narrowest diameter on a lateral view cineangiogram varied
between 1 and 15 mm with a median of 4 mm. Twenty
PDAs measured 8 or more mm in diameter; ten were larger
than 10 mm. Data on pulmonary-to-systemic flow ratio
(Qp:Qs) were available in 169 patients and was 1.8 6 0.6
(mean 6 SD) with a range of 1.2 to 4.8. The PDA was
conical in shape in 164 patients, tubular in 56, short in 29
(some are aortopulmonary window type), miscellaneous
types in 25 and previous Rashkind device implantation in
10.
The PDAs were occluded with 15 mm devices in 140
patients, delivered via a 7F sheath. Twenty mm devices were
used in 115 patients, 25 mm devices in 15 patients, 30 mm
devices in six patients, and 35 mm devices in two patients.
Six patients received miscellaneous size devices. The latter
144 devices were implanted via 8F sheaths.
Immediate results. The device was successfully implanted
in 278 (98%) of 284 patients. In six (2%) patients, the device
pulled through the PDA. Transcatheter retrieval was un-
dertaken in three patients. In two of these patients a larger
device was implanted and the third patient was sent to
elective surgery. In the remaining three patients, surgical
retrieval of the device along with PDA ligation was under-
taken. No other complications were encountered.
The Qp:Qs (in the 169 subjects in whom it was mea-
sured) decreased from 1.8 6 0.6 to 1.09 6 0.19 (p , 0.001).
Complete occlusion by aortography was observed in 167
(60%) of 280 patients in whom the device was implanted,
including all 10 patients with residual shunts following
Rashkind device placement. Effective occlusion, defined as
trivial (n 5 79) or no (n 5 167) residual shunt on
echo-Doppler study (Table 1) within 24 hours after device
implantation, was achieved in 246 (88%) of 280 patients. All
types of PDAs including conical, tubular and short could be
occluded. There is no relationship between the length or
diameter of the PDA and the presence or absence of
effective occlusion. Continuous murmur disappeared in all
but four (1.4%) of 280 patients.
Small (n 5 34) or trivial (n 5 79) residual shunts were
present in 113 (40%) of 280 patients. Ductal shape did not
influence the percent residual shunt (p . 0.1) (Fig. 2A).
However, ductal size does influence the residual shunts; the
larger the ductal diameter, the greater was the prevalence of
residual shunt (p , 0.01) (Fig. 2B). This is in contradis-
tinction to effective occlusion (as defined in the preceding
paragraph) which is not influenced by the size of the PDA.
Follow-up results. Clinical , chest X-ray and
echocardiography-Doppler follow-up data were available
for review in 234 (84%) of 280 patients 1 to 60 months
Figure 1. Photograph of the modified buttoned device showing
the occluder (Occ), counter-occluder (COc) and polyurethane
folding plug (FP) covering (arrows) the button loop (BL). LW 5
loading wire.
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(median 24) after device implantation. Seven (2.5%)
patients required reintervention during follow-up. Two
patients underwent surgical ligation for residual shunt.
Two patients with hemolysis secondary to trivial residual
shunt also underwent surgical ligation. The remaining
three patients were treated by coil (n 5 2) or a second
buttoned device (n 5 1) implantation for occluding
residual shunts. Actuarial event-free rates are shown in
Figure 3.
The device was in position on chest x-ray and there was
no breakage of the radiopaque wire components of the
device seen. No endocarditis was observed during follow-up.
There was no clinical or echocardiographic evidence for
thrombus formation. No late embolization of the device
components nor device detachment were observed.
Echocardiography-Doppler studies revealed gradual in-
crease (p , 0.05 to ,0.01) in the number of subjects
without residual shunts (Fig. 4). Rates of resolution of
residual shunts are depicted in Figure 5. There have been no
instances of recanalization, i.e., no reappearance of the
shunt after it had been demonstrated closed by color
Doppler. No evidence for obstruction in the descending
aorta or in the left pulmonary artery was observed.
Figure 2. (A) Relationship of residual shunt (by echo-Doppler
within 24 hours of device implantation) with shape of the ductus;
note that there is no significant (p . 0.1) relationship. (B)
Relationship of residual shunt (within 24 hours of procedure by
echo-Doppler) to the size of ductus is shown; note higher
incidence of residual shunts with larger ducts.
Figure 3. Transcatheter closure of PDA. Graph showing actuarial
event-free rates after transvenous buttoned device occlusion of
patent ductus arteriosus.
Figure 4. Prevalence of residual shunts following buttoned device
occlusion of patent ductus arteriosus. Note that there was gradual
increase in the number of subjects without residual shunts while
the number of patients with residual shunt decreased gradually.
McNemar’s pairwise comparison of data was used and Bonferroni
correction was applied. The rate of change is statistically significant
(p , 0.05 to ,0.01). NS 5 no residual shunt; SS 5 small residual
shunt; TS 5 trivial residual shunt.
Figure 5. Actuarial resolution (p , 0.01) of residual shunts
following buttoned device closure of patent ductus arteriosus.
Reinterventions are not included in the calculation of resolution of
residual shunts.
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Folding plug device. Ten patients, ages 3 to 39 years,
weighing 9 to 70 (median 12) kg underwent transcatheter
occlusion with the folding plug BD delivered via 8F sheaths.
The PDAs measured 4 to 11 mm (median 8) at their
narrowest diameter. This device with the occluder at the
aortic end of the ductus, folding plug in the ductal lumen
and counter-occluder in the pulmonary artery, produced
complete occlusion in all 10 patients, demonstrated by
aortography 15 minutes following device implantation (Fig.
6) and by color Doppler echocardiography on the morning
following device placement. There was no evidence for
obstruction either in the aorta or in the left pulmonary
artery. Follow-up was available one to three months follow-
ing the procedure. The ductus remains closed by color
Doppler studies.
DISCUSSION
In a preliminary study of 14 children reported in 1993 (2),
feasibility, safety and effectiveness of the buttoned device in
transcatheter occlusion of PDA was demonstrated. How-
ever, because of the limited number of patients studied, no
definitive conclusions could be drawn. Furthermore, the
follow-up duration was short. In the current study involving
a large group of children and adults, feasibility, safety and
effectiveness of the buttoned device closure of PDA is
reconfirmed. Effective occlusion was accomplished irrespec-
tive of the size (diameter) and shape (conical, tubular or
short) of the ductus, although complete occlusion rate was
lower with larger PDAs (Fig. 2B). Both short and long
PDAs could be occluded because of adjustable button
design of the button loop.
Whereas effective occlusion rates, defined as trivial or no
shunt, are high (88%), residual shunts were observed in 40%
patients. These residual shunts, however, diminished and
resolved with time (Fig. 5). The indications for closure in
many of these patients are prevention of bacterial endocar-
ditis. Therefore, these patients are potentially at risk for
development of subacute bacterial endocarditis prior to
disappearance of the residual shunt. For this reason, it
would be better if the device or method could be modified
such that complete closure would occur at the time of device
implantation. Because of this, the device was modified by
incorporating polyurethane foam over the button loop, the
folding plug. With this modified device, complete occlusion
at the time of implantation was achieved in all patients.
Future clinical trials will utilize this modified device.
Patients with residual shunts at follow-up beyond one
year after device implantation may need reocclusion because
the rate of spontaneous closure decreases after the first year
(Fig. 5). Of the surgical, second buttoned device and coil
options, we prefer coil occlusion (9,10) for small residual
shunts and a second buttoned device for moderate to large
residual PDAs.
Since the description of the first transcatheter method of
closure of PDA by Porstmann et al. (11,12), a variety of
devices have been described (6,7,9,13–19) which are tabu-
lated (Table 2). Most of the devices require large delivery
sheath and some require transarterial delivery of the occlud-
ing device (Table 2). Long-term follow-up results for most
of the devices are scant (17–19). Longer follow-up results
with Rashkind device show significant incidence of residual
shunts (20,21), especially with large PDAs.
At the present time surgical (22), video-assisted thoraco-
scopic (23) and several transcatheter (6,7,9,11–19) methods
are available for closure of PDA. In the absence of prospec-
tive, randomized clinical trials, it is difficult to accurately
compare relative risks and benefits of these procedures. But
the morbidity and length of hospitalization associated with
most transcatheter methods appears less than that experi-
enced with surgical (24) and video-assisted thoracoscopic
(23) procedures. Residual shunt appears to be present with
all types of PDA closure (20,21,24–26) and may be depen-
dent upon sensitivity of the method used (for example,
auscultatory vs. color Doppler) for detection of residual
shunt.
Figure 6. Selected cineangiographic frames from aortograms in right anterior oblique view prior to (a) and 15 minutes following (b)
transvenous implantation of buttoned device with a folding plug demonstrating a large patent ductus arteriosus (PDA) in a, which is
completely occluded following device (D) implantation (b). Ao 5 aorta; PA 5 pulmonary artery.
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Recently, Cambier et al. (9) have described transcatheter
closure of PDA using Gianturco coils (27). Because of
small-sized catheters needed to deliver the coil, ease with
which the technique can be learned and to incur less expense
several groups of workers, referenced extensively elsewhere
(28), have adopted this method. Further modification of the
method by introducing detachable version (29), antegrade
and multiple coil approach (30), snare-assisted coil delivery
(31), temporary balloon occlusion during coil placement
(32), double-disk shaped diabolo configuration design (18),
increasing the wire diameter to 0.052-in (33) and five-loop
coil design (10) have been undertaken with success. Based
on extensive review of this subject (28,34), we concluded
that coil occlusion is appropriate for the ductus measuring
#3.5 mm. Larger PDAs (.3.5 mm) may be best closed by
other methods. The buttoned device presented in this study
appears suitable in occluding such PDAs. Effective occlu-
sion can be accomplished even in large PDAs with the
regular buttoned device. Incorporation of folding plug
appears to achieve complete occlusion at the time of device
implantation.
Limitations. This is a retrospective review of multiinstitu-
tional experience with PDA closure and has limitations
associated with any retrospective multiinstitutional study.
The follow-up echocardiographic data pertaining to residual
shunts was analyzed at the investigators’ institution and may
introduce a bias. Analysis of these data at a core laboratory
as has recently been advocated in coronary interventional
studies may help reduce such a bias. Lack of follow-up data
in 16% of the patients is another limitation of this study.
In conclusion, feasibility, safety and efficacy of trans-
venous occlusion of PDA with buttoned device is demon-
strated and confirmed in this study. Although it is feasible
to use this device for small PDAs, coil occlusion is probably
more appropriate for such PDAs. Modified buttoned device
with folding plug may be an optimal choice for moderate
and large PDAs.
APPENDIX
The following institutions and investigators participated in
the international buttoned device trial for transcatheter
closure of patent ductus arteriosus: All India Institute of
Medical Sciences, U. Kaul, MD; Anzhen Hospital, Beijing,
China, C. Han, MD; Batra Hospital and Medical Research
Center, New Delhi, India, R. Lochan, MD; East Hospital,
Gothenberg, Sweden, L. Solymar, MD; G. B. Pant Hospi-
tal, New Delhi, India, R. Arora, MD; German Heart Center,
Berlin, Germany, F. Berger, MD; Guandong Cardiovascular
Institute, Guandong, China, C. Chen, MD; Hospital do
Coraca˜o de Ribeira˜o Preto, Ribeira˜o Preto, Brazil, J. Haddad,
MD; Hospital Reina Sofia, Cardoba, Spain, J. Suarez de
Lezo, MD; King Edward Memorial Hospital, Mumbai,
India, H. Kulkarni, MD; Nizam Institute of Medical Sciences,
Hyderabad, India, S. Jai Shankar, MD and B. Somaraju,
MD; Ospedale Clinicizzata San Donato, San Donato
Milanese, Italy, E. Onorato, MD; Royal Liverpool Children’s
NHS Trust, Alder Hey, Liverpool, England, K. Walsch,
MD; Saint Louis University Health Sciences Center, St.
Louis, MO, R. Bach, MD and P. S. Rao, MD; Sejong
General Hospital, Puchon, Korea, S. H. Kim, MD; Sri
Venkateswara University Hospital, Tirupathi, India,
S. Agarwal, MD; Universite´ de Lille, Lille, France, C. Rey,
MD; Universite´ de Nancy, Nancy, France, F. Marcon, MD
and A. M. Worms; University of Wisconsin Children’s Hos-
pital, Madison, WI, P. S. Rao, MD and A. W. Wilson,
MD; Wonju Christian Hospital, Wonju, Korea, H. Y. Lee,
MD and J. H. Yoon, MD; Yonsei University Hospital, Seoul,
Korea, J. Y. Choi, MD.
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Table 2. Clinically Used Devices for Transcatheter Occlusion of Patent Ductus Arteriosus
Device





Porstmann’s Ivalon plug 18F Arterial
Rashkind’s hooked umbrella device 6F Arterial
Rashkind’s double-disc device 8F or 11F Venous
Clamshell device 11F Venous
Buttoned device 7F or 8F Venous
Botallo-occluder 10F to 16F Venous
Gianturco coils 4F or 5F Arterial or Venous
Gianturco-Grifka sac 10F Venous
Duct Occlud pfm 4F Venous or Arterial
Amplatzer duct occluder 6F Venous
Folding plug buttoned device 8F Venous
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